US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi

US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi Leqembi won accelerated approval by the FDA in January based on its ability to remove sticky amyloid plaques from the brain. The panel on Friday considered Eisai's large confirmatory trial designed to show the drug benefited patients. https://ift.tt/0NfGR1m

Comments

Popular posts from this blog

Women in India Report Higher Sleep Deprivation Than Men

Nadda reviews healthcare delivery mechanisms in Rajasthan, Maharashtra

ICMR to roll out multi-state study to expand palliative care access